One such mAb – MSB0010718C (termed avelumab) – is a human IgG1-based anti-PD-L1 mAb that has shown positive benefits across several tumor types (12), and therefore, may also show promise in HPV+ cervical cancer patients. Here, CD274 is linked to cervical carcinoma.